- 期刊
Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer
並列摘要
One of the proposed benefits of targeted therapies is reduced toxicity and improved quality of life. The approval of a new broad family of molecularly targeted anticancer drugs represents one of the most significant recent advances in clinical oncology. The growth of solid tumors is dependent on their capacity to acquire a blood supply. Much effort has been directed towards the development of drugs that disrupt or normalize this process for cancer therapy. Some tumors also contain vasculogenic mimicry channels consisting of cancer cells and their extracellular matrix. In solid tumors, vasculogenic mimicry has been found to be strongly correlated with advanced-stage disease and poor outcome. In this review article, we summarize the clinical use of small molecules and therapeutic antibodies as angiogenesis inhibitors and their toxic side effects. We discuss vasculogenic mimicry of solid tumors and describe strategies for identifying putative tumor vascular targets. We end by discussing the future prospects for the clinical use of vascular targeting in treatment of cancer.
被引用紀錄
延伸閱讀
- 李欣慈、趙詩瑾、廖珍娟、周桂如（2005）。A New Trend of Cancer Therapy: Targeted Therapy。腫瘤護理雜誌，5(2)，29-42。https://doi.org/10.6880/TJON.200512_5(2).03
- Yen, C. C. (2007). Angiogenesis-The Ultimate Target of Cancer Treatment. 中華民國癌症醫學會雜誌, 23(3), 45-55. https://doi.org/10.6588/JCOS.2007.23.3.1
- Trinh, D. K. (2020). Development of a Novel CXCR4 Antagonist for Cancer Therapy [master's thesis, National Tsing Hua University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0016-2502202114193209
- Ong, C. W., & Han, J. L. (2002). Some Aspect of Anticancer Drug Activation. The Chinese Pharmaceutical Journal, 54(5), 313-329. https://doi.org/10.7019/CPJ.200210.0313
- 林蓉萱、陳幼貴、陳怡君（2021）。Antibody-Drug Conjugates for Cancer Therapy。腫瘤護理雜誌，21(2)，13-19。https://doi.org/10.6880/TJON.202112_21(2).02